Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.

NCT04147871 is registered in ClinicalTrials.gov with Advicenne Pharma as lead sponsor.

NCT NCT04147871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04147871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.
Lead sponsor
Advicenne Pharma
Phase
Phase 2/3
Overall status
Withdrawn
Start date
March 1, 2024
Completion date
June 1, 2025
Enrollment
0 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cystinuria